ASH17: argenx shares pop on autoimmune data

In a busy day, argenx reported positive topline results at ASH and announced a proposed U.S. public offering, shooting its stock up by over 80%.

By Suzanne Elvidge • Dec. 12, 2017

ASH17: J&J's Darzalex delivers combo win

Inserting the antibody into standard combo regimens is a key part of J&J's plan for expanding use of the drug into the frontline setting. 

By Ned Pagliarulo • Dec. 12, 2017

Explore the Trendline➔

Vaccine development

Vaccine developers are investing in shots for RSV, influenza and pneumococcal disease in a newly uncertain regulatory climate.

By BioPharma Dive staff

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

Mixed data from the biotech's hemophilia A candidate disappointed investors primed by BioMarin's compelling results.  

By Ned Pagliarulo • Dec. 11, 2017

OS miss prompts Lilly to drop Cyramza expansion

While the cancer drug improved PFS in a gastric cancer study, it didn't significantly improve overall survival — limiting its competitiveness.

By Suzanne Elvidge • Dec. 11, 2017

ASH17: Benefit of Gilead's CAR-T remains durable over longer term

More than a year after infusion, four in ten patients treated with Yescarta showed no signs of lymphoma. 

By Ned Pagliarulo • Dec. 10, 2017

ASH17: Seattle Genetics sees market opportunity in cancer combo success

Replacing a toxic chemo agent could make Adcetris a new standard therapy to treat frontline Hodgkin lymphoma.

By Ned Pagliarulo • Dec. 10, 2017

ASH17: bluebird bio makes strides in CAR-T, gene therapy

New data on the biotech's multiple myeloma CAR-T therapy were particularly impressive, boosting investor confidence. 

By Ned Pagliarulo • Dec. 9, 2017

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

Updated results from an early trial suggest an effective gene therapy for hemophilia A could be within reach.

By Ned Pagliarulo • Dec. 9, 2017

Pfizer's PARP inhibitor showcases efficacy in late-stage trial

For breast cancer patients with specific mutations, treatment with talazoparib resulted in three additional months of progression-free survival versus chemo. 

By Jacob Bell • Dec. 8, 2017

Prescribed Reading: Dealmaking begins to pick up as 2018 approaches

It's been a slow year for deals, but it looks like Gilead's buy of Kite could be a catalyst for more M&A. 

By Lisa LaMotta • Dec. 8, 2017

Arrowhead data hits the target in chronic hep B

New data from the Arrowhead ARC-520 Phase 2 trial in chronic hepatitis B points to a sustained host response.

By Suzanne Elvidge • Dec. 8, 2017

Sage stock soars with positive Phase 2 in major depression

Hope increases for patients with major depressive disorder as Sage Therapeutics' SAGE-217 meets its primary endpoint, with rapid and durable effects over six weeks of treatment.

By Suzanne Elvidge • Dec. 8, 2017

Chasing leaders, Juno rides CAR-T momentum into ASH

This year's ASH conference will be an important milestone in Juno's comeback bid, showcasing early progress of its lead CAR-T therapy in lymphoma. 

By Ned Pagliarulo • Dec. 7, 2017

Roche's Tecentriq combo cuts risk of lung cancer progression

Detailed results from the Swiss pharma's IMpower150 study boost Tecentriq's profile in the frontline lung cancer setting.

By Ned Pagliarulo • Dec. 7, 2017

Madrigal NASH data sounds a sweet note, stock soars

The market is playing the biotech's tune, as positive NASH data pleases shareholders.

By Suzanne Elvidge • Dec. 7, 2017

FDA cautiously lifts holds on combo studies of checkpoint inhibitors

Concerns of a potential class-wide safety risk had prompted the agency to shut down several studies pairing PD-1/L1 blockers with immunomodulatory drugs in multiple myeloma.

By Ned Pagliarulo • Dec. 6, 2017

Galectin drops 40% on negative NASH result

The biotech's stock took a major hit when its NASH drug didn't work in the overall study population.

By Lisa LaMotta • Dec. 5, 2017

J&J, Sanofi ranked best for clinical trial transparency

Both companies had 100% transparency rates related to new drugs they received approval for in 2014, according to a new study from Bioethics International.

By Jacob Bell • Dec. 5, 2017

Ra shares tank on Soliris comparison

Despite positive data for RA101495, the markets haven't seemed impressed, and stock value has dropped by over 37% at close.

By Suzanne Elvidge • Dec. 5, 2017

Ironwood pushing through mid-stage trials with nephropathy drug

Safety and PK studies showed early signs of benefits for Ironwood's lead pipeline candidate.

By Suzanne Elvidge • Dec. 5, 2017

Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit

Disclosure of the setback came on the heels of a damaging admission by Sanofi that its dengue vaccine could intensify subsequent infections in certain patients. 

By Ned Pagliarulo • Dec. 4, 2017

7 Biopharmas to watch at ASH 2017

This year's ASH meeting looks to be a key milestone for several closely watched cell and gene therapy companies. 

By Ned Pagliarulo • Dec. 4, 2017

Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC

Imfinzi's miss in non-small cell lung cancer was a huge setback for the British pharma and could relegate the drug as a never-was in the checkpoint inhibitor race.

By Lisa LaMotta • Dec. 4, 2017

The BioPharma Dive Awards for 2017

The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 4, 2017

Disruption of the Year: Long-Acting Hemophilia Drugs

Longer-acting treatments and gene therapies are likely to steal away hundreds of millions of dollars worth of revenue from established products in the coming years.

By Jacob Bell • Dec. 4, 2017